1. Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease.

    Alzheimer's Research & Therapy 7(1):36 (2015) PMID 26064192 PMCID PMC4461930

    The negative efficacy study examining the γ-secretase inhibitor semagacestat in mild to moderate Alzheimer's disease (AD) included a number of biomarkers of the disease as well as safety outcomes. We analyzed these data to explore relationships between drug exposure and pharmacodynamic effects a...
  2. Estimating long-term multivariate progression from short-term data.

    Alzheimer's & Dementia 10(5 Suppl):S400 (2014) PMID 24656849 PMCID PMC4169767

    Diseases that progress slowly are often studied by observing cohorts at different stages of disease for short periods of time. The Alzheimer's Disease Neuroimaging Initiative (ADNI) follows elders with various degrees of cognitive impairment, from normal to impaired. The study includes a rich pa...
  3. Estimating long-term multivariate progression from short-term data

    Alzheimer's & Dementia 10(5):S400 (2014)

    Motivation Diseases that progress slowly are often studied by observing cohorts at different stages of disease for short periods of time. The Alzheimer's Disease Neuroimaging Initiative (ADNI) follows elders with various degrees of cognitive impairment, from normal to impaire...
  4. Estimating long-term multivariate progression from short-term data.

    Alzheimer's & Dementia 10(5 Suppl):S400 (2014) PMID 24656849 PMCID PMC4169767

    Diseases that progress slowly are often studied by observing cohorts at different stages of disease for short periods of time. The Alzheimer's Disease Neuroimaging Initiative (ADNI) follows elders with various degrees of cognitive impairment, from normal to impaired. The study includes a rich pa...
  5. Estimating long-term multivariate progression from short-term data.

    Alzheimer's & Dementia 10(5 Suppl):S400 (2014) PMID 24656849 PMCID PMC4169767

    Diseases that progress slowly are often studied by observing cohorts at different stages of disease for short periods of time. The Alzheimer's Disease Neuroimaging Initiative (ADNI) follows elders with various degrees of cognitive impairment, from normal to impaired. The study includes a rich pa...
  6. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.

    JAMA Neurology 71(8):961 (2014) PMID 24886908

    As Alzheimer disease (AD) research moves to intervene in presymptomatic phases of the disease, we must develop outcome measures sensitive to the earliest disease-related changes. To demonstrate the feasibility of a cognitive composite outcome for clinically normal elderly participants with evide...
  7. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.

    JAMA Neurology 71(8):961 (2014) PMID 24886908

    As Alzheimer disease (AD) research moves to intervene in presymptomatic phases of the disease, we must develop outcome measures sensitive to the earliest disease-related changes. To demonstrate the feasibility of a cognitive composite outcome for clinically normal elderly participants with evide...
  8. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.

    JAMA Neurology 71(8):961 (2014) PMID 24886908

    As Alzheimer disease (AD) research moves to intervene in presymptomatic phases of the disease, we must develop outcome measures sensitive to the earliest disease-related changes. To demonstrate the feasibility of a cognitive composite outcome for clinically normal elderly participants with evide...
  9. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.

    JAMA Neurology 71(8):961 (2014) PMID 24886908 PMCID PMC4439182

    As Alzheimer disease (AD) research moves to intervene in presymptomatic phases of the disease, we must develop outcome measures sensitive to the earliest disease-related changes. To demonstrate the feasibility of a cognitive composite outcome for clinically normal elderly participants with evide...
  10. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.

    JAMA Neurology 71(8):961 (2014) PMID 24886908

    As Alzheimer disease (AD) research moves to intervene in presymptomatic phases of the disease, we must develop outcome measures sensitive to the earliest disease-related changes. To demonstrate the feasibility of a cognitive composite outcome for clinically normal elderly participants with evide...
  11. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease.

    Neurology 82(17):1536 (2014) PMID 24696507 PMCID PMC4011464

    To examine safety, tolerability, and efficacy of PF-04494700, an inhibitor of the receptor for advanced glycation end products (RAGE), in mild to moderate Alzheimer disease (AD). Double-blind, placebo-controlled trial at 40 academic centers (United States). Subjects with AD and Mini-Mental State...
  12. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease.

    Neurology 82(17):1536 (2014) PMID 24696507 PMCID PMC4011464

    To examine safety, tolerability, and efficacy of PF-04494700, an inhibitor of the receptor for advanced glycation end products (RAGE), in mild to moderate Alzheimer disease (AD). Double-blind, placebo-controlled trial at 40 academic centers (United States). Subjects with AD and Mini-Mental State...
  13. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease.

    Neurology 82(17):1536 (2014) PMID 24696507 PMCID PMC4011464

    To examine safety, tolerability, and efficacy of PF-04494700, an inhibitor of the receptor for advanced glycation end products (RAGE), in mild to moderate Alzheimer disease (AD). Double-blind, placebo-controlled trial at 40 academic centers (United States). Subjects with AD and Mini-Mental State...
  14. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

    New England Journal of Medicine 370(4):311 (2014) PMID 24450890

    Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. In two phase 3, double-...
  15. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

    New England Journal of Medicine 370(4):311 (2014) PMID 24450890

    Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. In two phase 3, double-...
  16. A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

    New England Journal of Medicine 369(4):341 (2013) PMID 23883379

    Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatm...
  17. A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

    New England Journal of Medicine 369(4):341 (2013) PMID 23883379

    Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatm...
  18. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly.

    Neuropsychology 27(4):391 (2013) PMID 23876113 PMCID PMC3831285

    This study examined the impact of age and apolipoprotein E (APOE) genotype on the rate of cognitive decline in nondemented elderly participants in a simulated Alzheimer's disease (AD) primary prevention treatment trial carried out by the Alzheimer's Disease Cooperative Study. Cognitive tests wer...
  19. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly.

    Neuropsychology 27(4):391 (2013) PMID 23876113 PMCID PMC3831285

    This study examined the impact of age and apolipoprotein E (APOE) genotype on the rate of cognitive decline in nondemented elderly participants in a simulated Alzheimer's disease (AD) primary prevention treatment trial carried out by the Alzheimer's Disease Cooperative Study. Cognitive tests wer...
  20. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly.

    Neuropsychology 27(4):391 (2013) PMID 23876113 PMCID PMC3831285

    This study examined the impact of age and apolipoprotein E (APOE) genotype on the rate of cognitive decline in nondemented elderly participants in a simulated Alzheimer's disease (AD) primary prevention treatment trial carried out by the Alzheimer's Disease Cooperative Study. Cognitive tests wer...